waiting on:
KOS-862 (Epothilone D, a polyketide product that exhibits the same
MOA as paclitaxel) is in phase II as monotherapy for 2nd line
metastatic breast cancer and hormone refractory prostate cancer
(HRPC), and in phase Ib combination studies - partnered with Roche - follow-on compound (KOS-1584) is in phase I.
Hsp90 (heat shock
protein 90) inhibitors are being developed in collaboration with the NCI,
including 17-AAG, a first generation geldanamycin analog. A proprietary
formulation of 17-AAG, KOS-953, is in phase I and phase II trials for
multiple myeloma and HER2 metastatic breast cancer, and a 2ndgeneration
geldanamycin analog, KOS-1022 (DMAG), is in phase I.
Cancer KOS-862 II
June 2005: KOS-862 phase II data in
breast cancer at ASCO
for some strange reason, the stock is tempting at these levels, part to trade again in anticipation of asco, and acquire another chunk of long-term hold.
still sitting on my original batch from $4. |
